A Phase 2 interventional study of nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 36 sites in 13 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2021-04-22.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 31st largest by enrollment, is one of 11 that started in 2013, is one of 25 in phase 2, and was the 44th registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 26 more countries
Ages 7–100
Medical College of Wisconsin · Sites in United States
Ages 18+
By country, each count listing its studies:
nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 32 · Phase 3 16 · Phase 4 12
First in 2001; this study’s year is marked. 11 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 55 across the 66 interventional studies. Of the 54 that completed or were terminated, 29 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 66 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis: 9 open now, 13 under way, 2 of them phase 3. Of 73 finished, 35 (48%) have results posted.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 34th largest by enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2013, is one of 19 in phase 2, and was the 53rd registered.
Novartis’s Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 92 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety, efficacy and pharmacokinetics of nilotinib over time in the Ph+ chronic myelogenous leukemia (CML) in pediatric patients (from 1 to \<18 years).
The study was designed as a multi-center, open-label, non-controlled phase II study to assess efficacy, safety and PK parameters of 230 mg/m2 twice daily nilotinib in pediatric patients (1 to \<18 years old). The study population consisted of three cohorts of Ph+ CML pediatric patients:
Based on enrollment forecasts as of Jan 2015, and to reflect the agreements with the US FDA and the PDCO, the study remained open for enrollment until the targeted number of 50 patients with at least 15 newly diagnosed Ph+CML patients was achieved or until 31May2015, whichever was later.
Patients who completed the study were treated with nilotinib for a total of 66 cycles of 28 days unless the patient prematurely discontinued study treatment.
The primary analysis cut-off date was the date when all patients enrolled in the trial either completed their visit for treatment cycle 12 or had discontinued study treatment early (EoT/early discontinuation visit). These analyses were reported in the 12-cycle clinical study report (CSR). A 24-cycle analysis was done when all patients had either completed their 24-cycle treatment visit or had discontinued study treatment early.
At trial end, a final comprehensive CSR of all data collected during the trial was produced.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.
Drug: nilotinib
Resistant or Intolerant to either imatinib or dasatinib
Drug: nilotinib
Resistant or intolerant to either imatinib or dasatinib - at the end no patients were enrolled in this arm.
Drug: nilotinib
Nilotinib supplied in 50mg, 150mg, and 200mg capsules. It was administered orally at 230mg/m2, twice daily for up to 66 cycles (1 cycle = 28 days). Dose administration was rounded to the nearest 50mg dose (to a maximum dose of 400mg).
Also known as: AMN107
Rate of Major Molecular Response (MMR) at 6 Cycles for Ph+ CML CP Patients Resistant or Intolerant to Imatinib or Dasatinib
MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. A patient was counted as having MMR at 6 cycles if the patient met the MMR criteria at the Cycle 6 Visit.
Time frame: 6 cycles
MMR Rate by 12 Cycles in Newly Diagnosed Ph+ CML-CP Patients
MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. A patient was counted as having MMR by 12 cycles if the patient met the MMR criteria at least once at any time between first study drug intake and Cycle 12 visit included.
Time frame: 12 cycles
Rate of Complete Cytogenic Response (CCyR) at 12 Cycles in Newly Diagnosed Ph+ CML-CP Patients
Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as CCyR at 12 cycles if the patient met the CCyR criteria at the Cycle 12 Visit.
Time frame: 12 cycles
MMR Rate by Time Points in Ph+ CML-CP Patients Resistant or Intolerant to Imatinib or Dasatinib
Major molecular response (MMR) was defined as BCR-ABL/ABL % ≤ 0.1% by IS as measured by RQ-PCR, confirmed by duplicate analysis of the same sample.
Time frame: By 3, 6, 9 , 12, 24, 36, 48, 66 cycles ( 1 cycle = 28 days)
MMR Rate by Time Points in Newly Diagnosed Ph+ CML-CP Patients
Major molecular response (MMR) was defined as BCR-ABL/ABL % ≤ 0.1% by IS as measured by RQ-PCR, confirmed by duplicate analysis of the same sample.
Time frame: by 3, 6, 9, 12, 24, 36, 48, 66 cycles (1 cycle = 28 days)
Best BCR-ABL Ratio Categories for Resistant/Intolerant Ph+ CML - Overall
MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. BCR-ABL ratio by percentage: \> 0.0032 to ≤ 0.01% is equal to a log reduction category of \>= 4 to \<4.5 -log reduction (MR4); BCR-ABL ratio by percentage: \<=0.0032% is equal to a log reduction category of \>= 4.5-log reduction (MMR4.5)
Time frame: up to 66 cycles (1 cycle = 28 days)
Best BCR-ABL Ratio Categories for Newly Diagnosed Ph+ CML-CP - Overall
MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. BCR-ABL ratio by percentage: \> 0.0032 to ≤ 0.01% is equal to a log reduction category of \>= 4 to \<4.5 -log reduction (MR4); BCR-ABL ratio by percentage: \<=0.0032% is equal to a log reduction category of \>= 4.5-log reduction (MMR4.5)
Time frame: up to 66 cycles (1 cycle = 28 days)
Time to First MMR Among Imatinib or Dasatinib Resistant or Intolerant CML-CP Patients Who Achieved MMR
Time from first study drug intake to first MMR amongst imatinib or dasatinib resistant or intolerant patients with CML-CP computed only for patients who achieved MMR.
Time frame: From first dosing to the first MMR within 66 cycles period
Time to First MMR Among Newly Diagnosed Ph+ CML-CP Patients Who Achieved MMR
Time to MMR is the time from first study drug intake to first major molecular response computed only for participants who achieved MMR.
Time frame: From first dosing to the first MMR within 66 cycles period
Duration of First MMR Among Patients Who Were Resistant or Intolerant to Either Imatinib or Dasatinib Who Achieved MMR
Duration of MMR is defined as the time between the date of the first MMR and the date of confirmed loss of MMR (i.e. the earliest of confirmed loss of MMR, CML-related death or progression to AP or BC). Participants without loss of MMR were censored at the last molecular assessment date.
Time frame: from MMR until confirmed loss of MMR (Assessed up to 66 cycles)
Duration of First MMR Among Newly Diagnosed Patients Who Achieved MMR
Duration of MMR is defined as the time between the date of the first MMR and the date of confirmed loss of MMR (i.e. the earliest of confirmed loss of MMR, CML-related death or progression to AP or BC). Participants without loss of MMR were censored at the last molecular assessment date.
Time frame: from MMR until confirmed loss of MMR (Assessed up to 66 cycles)es)
Best Complete Cytogenetic Response (CCyR) Categories in Ph+ CML-CP Patients Resistant or Intolerant to Imatinib or Dasatinib - Overall
* Complete cytogenetic response (CCyR) - 0% Ph+ metaphases * Partial cytogenetic response (PCyR) - \>0 to 35% Ph+ metaphases * Minor cytogenetic response (mCyR) - \>35 to 65% Ph+ metaphases * Minimal - \>65 to 95% Ph+ metaphases * None - \>95 to 100% Ph+ metaphases * Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.
Time frame: up to 66 cycles
Best Complete Cytogenetic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients - Overall
Complete cytogenetic response (CCyR) - 0% Ph+ metaphases No response - \>95 to 100% Ph+ metaphases
Time frame: up to 66 cycles
Summary of Time to First Complete Cytogenic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients
Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as having CCyR by 6 cycles (respectively 12 cycles) if the patient met the CCyR criteria at least once at any time between first study drug intake and cycle 6 (cycle 12 respectively) visit included.
Time frame: From first dosing to the first CCyR up to 66 cycles
Kaplan-Meier Estimates of Time to First Complete Cytogenic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients
Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as having CCyR by 6 cycles (respectively 12 cycles) if the patient met the CCyR criteria at least once at any time between first study drug intake and cycle 6 (cycle 12 respectively) visit included.
Time frame: From first dosing to the first CCyR up to 66 cycles
Kaplan-Meier Estimates of Duration of First Complete Cytogenic Response (CCyR) Among Patients Who Achieved CCyR in Newly Diagnosed Ph+ CML-CP Patients
Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as having CCyR by 6 cycles (respectively 12 cycles) if the patient met the CCyR criteria at least once at any time between first study drug intake and cycle 6 (cycle 12 respectively) visit included.
Time frame: From CCyR to loss of CCyR up to 66 cycles
Best Major Cytogenetic Response (MCyR) Rate by Time Point in Newly Diagnosed Ph+ CML Patients
Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.
Time frame: 6, 12, 18, 24, 36, 48, 66 cycles
Summary of Time to First Major Cytogenetic Response (MCyR) Among Patients Who Achieved MCyR in Newly Diagnosed CML-CP Patients
Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.
Time frame: up to 66 cycles
Kaplan-Meier Estimates of Time to First Major Cytogenetic Response (MCyR) in Newly Diagnosed CML-CP Patients
Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.
Time frame: up to 66 cycles
Best Complete Hematological Response (CHR) by Time Point
Complete Hematological Response (CHR) was defined as * WBC count \<10×109/L * platelet count \<450×109/L * basophils \<5% * no blasts and promyelocytes in peripheral blood * myelocytes+metamyelocytes \<5% in peripheral blood * no evidence of extramedullary disease, including spleen and liver * Assessment confirmation after at least 4 weeks for newly diagnosed Ph+ CML-CP
Time frame: cycle 3, 6, 9, 12, 18, 24, 36, 48, 66
Summary of Time to First Complete Hematological Response (CHR) Among Patients Who Achieved Confirmed CHR in Newly Diagnosed CML-CP Patients
Complete Hematological Response (CHR) was defined as * WBC count \<10×109/L * platelet count \<450×109/L * basophils \<5% * no blasts and promyelocytes in peripheral blood * myelocytes+metamyelocytes \<5% in peripheral blood * no evidence of extramedullary disease, including spleen and liver * Assessment confirmation after at least 4 weeks for newly diagnosed Ph+ CML-CP
Time frame: from first dosing to CHR, UP TO 66 CYCLES
Kaplan-Meier Estimates of Time to First Complete Hematological Response (CHR) in Newly Diagnosed CML-CP Patients
Complete Hematological Response (CHR) was defined as * WBC count \<10×109/L * platelet count \<450×109/L * basophils \<5% * no blasts and promyelocytes in peripheral blood * myelocytes+metamyelocytes \<5% in peripheral blood * no evidence of extramedullary disease, including spleen and liver * Assessment confirmation after at least 4 weeks for newly diagnosed Ph+ CML-CP
Time frame: from first dosing to CHR, UP TO 66 CYCLES
Time to Disease Progression for Imatinib or Dasatinib Resistant or Intolerant CML-CP Patients - Kaplan-Meier Estimates
Time to disease progression is the time from the date of first study drug intake to the date of event defined as the first progression to AP or BC (from CP) or to BC (from AP) or the date of CML-related death occurring on treatment, whichever was earlier.
Time frame: From first dosing to the disease progression within 66 cycles
Event Free Survival in Imatinib/Dasatinib Resistant/Intolerant CML-CP Patients
Event Free Survival is defined as the time from the date of first study drug intake to the first occurrence of any of the following loss of CHR, loss of MCyR ( PCyR + CCyR), progression to AP/BC (from CP) or to BC (from AP), or death from any cause. (Including events only during treatment)
Time frame: From first dosing to the disease progression or death up to 66 cycles
Event Free Survival in Newly Diagnosed CML-CP Patients
Event Free Survival is defined as the time from the date of first study drug intake to the first occurrence of any of the following loss of CHR, loss of MCyR ( PCyR + CCyR), progression to AP/BC (from CP) or to BC (from AP), or death from any cause. (Including events only during treatment)
Time frame: From first dosing to the disease progression or death up to 66 cycles
Overall Survival (OS) in Imatinib/Dasatinib Resistant/Intolerant CML-CP - Kaplan-Meier Estimates
Overall survival is defined as the time from the date of first study drug intake to the date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of their last assessment for patients on study and date of last contact for patients in follow-up.
Time frame: from first dosing to death up to 66 cycles
Overall Survival (OS) in Newly Diagnosed CML-CP Patients
Overall survival is defined as the time from the date of first study drug intake to the date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of their last assessment for patients on study and date of last contact for patients in follow-up.
Time frame: from first dosing to death up to 66 cycles
Pharmacodynamics (BCR-ABL Transcript Levels Determined With Standard Protocols in Peripheral Blood): Best MMR Status by Cycle
BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. BCR-ABL transcript levels were summarized by cohort and time point. MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR.
Time frame: By 3, 6, 9, 12, 18, 24, 36, 48, 66 cycles
Pharmacokinetics (PK): Steady State Concentration of Nilotinib in Imatinib/Dasatinib Resistant/Intolerant CML-CP Patients
PK was analyzed only when all patients has completed 12 cycles on treatment or discontinued the study treatment early.
Time frame: Cycle 1 Day 8
Pharmacokinetics: Steady State Concentration of Nilotinib in Newly Diagnosed CML-CP Patients
PK was analyzed only when all patients has completed 12 cycles of treatment or discontinued the study treatment early.
Time frame: Cycle 1 Day 8
Growth Data: Abnormal Height Standard Deviation Scores (SDS) Changes by Cohort
To assess long term effect on growth, development and maturation of nilotinib treatment in pediatric patients with Ph+ CML in participants with both a baseline and post-baseline value.
Time frame: from first dosing to 66 cycles
Acceptability (Including Palatability) of Dose Forms Used After First Dose, Cycle 1 and Cycle 12 Study Drug Formulation
Acceptability of the study drug was evaluated from a questionnaire completed by patients, with the help from parents or caregivers at visits. The Questionnaire to capture patient assessment of palatability (very good to very bad) and acceptability of taking the medication (very easy to very hard to administration).
Time frame: up to Cycle 12
Mutational Assessment of BCR-ABL
Emerging signs of resistance to nilotinib
Time frame: up to 66 cycles
Long Term Effect of Nilotinib on Bone Metabolism
The summary of bone age and Dual-energy X-ray absorptiometry (DEXA) by cohort. Alteration of bone biochemical markers of hand and wrist X-Ray evaluation was observed in bone age standard deviation scores (SDS) and for bone mineral density for DEXA before and after treatment with nilotinib.
Time frame: Cycle 66
3 cohorts were planned based on disease classification. In 1 cohort no patients (pts) were enrolled so results presented are based on 2 cohorts. 34 imatinib/dasatinib resistant/intolerant CML-CP pts \& 25 newly diagnosed CML-CP pts were enrolled. 1 imatinib/dasatinib resistant/intolerant pt did not receive study drug \& was excluded from analysis.
| Milestone | Resistant/Intolerant Ph+ CML in CP | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|---|
| Started | 34 | 25 |
| Treated | 33 | 25 |
| Untreated | 1 | 0 |
| Completed | 19 | 10 |
| Not completed | 15 | 15 |
| Withdrew: Adverse event | 6 | 8 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Disease progression | 1 | 0 |
| Withdrew: Administrative problems | 3 | 4 |
| Withdrew: Protocol deviation | 2 | 0 |
| Withdrew: Untreated | 1 | 0 |
MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. A patient was counted as having MMR at 6 cycles if the patient met the MMR criteria at the Cycle 6 Visit.
| Percentage of participants | Resistant/Intolerant Ph+ CML in CP |
|---|---|
| Rate of Major Molecular Response (MMR) at 6 Cycles for Ph+ CML CP Patients Resistant or Intolerant to Imatinib or Dasatinib | 39.4 (22.9 to 57.9) |
MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. A patient was counted as having MMR by 12 cycles if the patient met the MMR criteria at least once at any time between first study drug intake and Cycle 12 visit included.
| Percentage of participants | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|
| MMR Rate by 12 Cycles in Newly Diagnosed Ph+ CML-CP Patients | 64.0 (42.5 to 82.0) |
Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as CCyR at 12 cycles if the patient met the CCyR criteria at the Cycle 12 Visit.
| Percentage of participants | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|
| Rate of Complete Cytogenic Response (CCyR) at 12 Cycles in Newly Diagnosed Ph+ CML-CP Patients | 64.0 (42.5 to 82.0) |
Major molecular response (MMR) was defined as BCR-ABL/ABL % ≤ 0.1% by IS as measured by RQ-PCR, confirmed by duplicate analysis of the same sample.
| Percentage of participants | Resistant/Intolerant Ph+ CML in CP |
|---|---|
| By cycle 3 | 36.4 (20.4 to 54.9) |
| By cycle 6 | 45.5 (28.1 to 63.6) |
| By cycle 9 | 51.5 (33.5 to 69.2) |
| By cycle 12 | 57.6 (39.2 to 74.5) |
| By cycle 18 | 57.6 (39.2 to 74.5) |
| By cycle 24 | 57.6 (39.2 to 74.5) |
| By cycle 36 | 57.6 (39.2 to 74.5) |
| By cycle 48 | 60.6 (42.1 to 77.1) |
| By cycle 66 | 60.6 (42.1 to 77.1) |
Major molecular response (MMR) was defined as BCR-ABL/ABL % ≤ 0.1% by IS as measured by RQ-PCR, confirmed by duplicate analysis of the same sample.
| Percentage of participants | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|
| By cycle 3 | 12.0 (2.5 to 31.2) |
| By cycle 6 | 52.0 (31.3 to 72.2) |
| By cycle 9 | 56.0 (34.9 to 75.6) |
| By cycle 12 | 64.0 (42.5 to 82.0) |
| By cycle 18 | 68.0 (46.5 to 85.1) |
| By cycle 24 | 68.0 (46.5 to 85.1) |
| By cycle 36 | 76.0 (54.9 to 90.6) |
| By cycle 48 | 76.0 (54.9 to 90.6) |
| By cycle 66 | 76.0 (54.9 to 90.6) |
MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. BCR-ABL ratio by percentage: \> 0.0032 to ≤ 0.01% is equal to a log reduction category of \>= 4 to \<4.5 -log reduction (MR4); BCR-ABL ratio by percentage: \<=0.0032% is equal to a log reduction category of \>= 4.5-log reduction (MMR4.5)
| Percentage of participants | Resistant/Intolerant Ph+ CML in CP |
|---|---|
| <=0.0032% | 12.1 |
| > 0.0032% - ≤ 0.01% | 15.2 |
| >0.01% - ≤ 0.1% | 33.3 |
| >0.1% - ≤ 1% | 21.2 |
| >1% - ≤ 10% | 9.1 |
| > 10% | 6.1 |
| Atypical transcripts at baseline | 3.0 |
MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. BCR-ABL ratio by percentage: \> 0.0032 to ≤ 0.01% is equal to a log reduction category of \>= 4 to \<4.5 -log reduction (MR4); BCR-ABL ratio by percentage: \<=0.0032% is equal to a log reduction category of \>= 4.5-log reduction (MMR4.5)
| Percentage of participants | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|
| ≤ 0.0032% | 44.0 |
| >0.0032% - ≤ 0.01% | 12.0 |
| >0.01% - ≤ 0.1% | 20.0 |
| >0.1% - ≤ 1% | 8.0 |
| >1% - ≤ 10% | 8.0 |
| >10% | 8.0 |
Time from first study drug intake to first MMR amongst imatinib or dasatinib resistant or intolerant patients with CML-CP computed only for patients who achieved MMR.
| months | Resistant/Intolerant Ph+ CML in CP |
|---|---|
| Time to First MMR Among Imatinib or Dasatinib Resistant or Intolerant CML-CP Patients Who Achieved MMR | 2.79 (0.03 to 5.75) |
Time to MMR is the time from first study drug intake to first major molecular response computed only for participants who achieved MMR.
| Months | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|
| Time to First MMR Among Newly Diagnosed Ph+ CML-CP Patients Who Achieved MMR | 5.59 (5.52 to 10.84) |
Duration of MMR is defined as the time between the date of the first MMR and the date of confirmed loss of MMR (i.e. the earliest of confirmed loss of MMR, CML-related death or progression to AP or BC). Participants without loss of MMR were censored at the last molecular assessment date.
| months | Resistant/Intolerant Ph+ CML in CP |
|---|---|
| Duration of First MMR Among Patients Who Were Resistant or Intolerant to Either Imatinib or Dasatinib Who Achieved MMR | NA (NA to NA) |
Duration of MMR is defined as the time between the date of the first MMR and the date of confirmed loss of MMR (i.e. the earliest of confirmed loss of MMR, CML-related death or progression to AP or BC). Participants without loss of MMR were censored at the last molecular assessment date.
| months | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|
| Duration of First MMR Among Newly Diagnosed Patients Who Achieved MMR | NA (NA to NA) |
* Complete cytogenetic response (CCyR) - 0% Ph+ metaphases * Partial cytogenetic response (PCyR) - \>0 to 35% Ph+ metaphases * Minor cytogenetic response (mCyR) - \>35 to 65% Ph+ metaphases * Minimal - \>65 to 95% Ph+ metaphases * None - \>95 to 100% Ph+ metaphases * Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.
| Percentage of participants | Resistant/Intolerant Ph+ CML in CP |
|---|---|
| Major cytogenetic response: Complete | 81.1 |
| Major cytogenetic response: Partial | 3.0 |
| Minimal | 3.0 |
| None | 3.0 |
| Missing | 9.1 |
Complete cytogenetic response (CCyR) - 0% Ph+ metaphases No response - \>95 to 100% Ph+ metaphases
| Percentage of participants | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|
| Best Complete Cytogenetic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients - Overall | 84.0 (63.9 to 95.5) |
Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as having CCyR by 6 cycles (respectively 12 cycles) if the patient met the CCyR criteria at least once at any time between first study drug intake and cycle 6 (cycle 12 respectively) visit included.
| months | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|
| Summary of Time to First Complete Cytogenic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients | 5.55 (5.49 to 5.59) |
Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as having CCyR by 6 cycles (respectively 12 cycles) if the patient met the CCyR criteria at least once at any time between first study drug intake and cycle 6 (cycle 12 respectively) visit included.
| months | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|
| Kaplan-Meier Estimates of Time to First Complete Cytogenic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients | 5.6 (5.5 to 5.6) |
Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as having CCyR by 6 cycles (respectively 12 cycles) if the patient met the CCyR criteria at least once at any time between first study drug intake and cycle 6 (cycle 12 respectively) visit included.
| months | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|
| Kaplan-Meier Estimates of Duration of First Complete Cytogenic Response (CCyR) Among Patients Who Achieved CCyR in Newly Diagnosed Ph+ CML-CP Patients | NA (NA to NA) |
Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.
| Percentage of participants | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|
| by cycle 6 | 88.0 (68.8 to 97.5) |
| by cycle 12 | 88.0 (68.8 to 97.5) |
| by cycle 18 | 88.0 (68.8 to 97.5) |
| by cycle 24 | 88.0 (68.8 to 97.5) |
| by cycle 36 | 88.0 (68.8 to 97.5) |
| by cycle 48 | 88.0 (68.8 to 97.5) |
| by cycle 66 | 88.0 (68.8 to 97.5) |
Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.
| months | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|
| Summary of Time to First Major Cytogenetic Response (MCyR) Among Patients Who Achieved MCyR in Newly Diagnosed CML-CP Patients | 5.55 (5.52 to 5.59) |
Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.
| months | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|
| Kaplan-Meier Estimates of Time to First Major Cytogenetic Response (MCyR) in Newly Diagnosed CML-CP Patients | 5.55 (5.52 to 5.59) |
Complete Hematological Response (CHR) was defined as * WBC count \<10×109/L * platelet count \<450×109/L * basophils \<5% * no blasts and promyelocytes in peripheral blood * myelocytes+metamyelocytes \<5% in peripheral blood * no evidence of extramedullary disease, including spleen and liver * Assessment confirmation after at least 4 weeks for newly diagnosed Ph+ CML-CP
| Percentage of participants | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|
| by cycle 3 | 76.0 (54.9 to 90.6) |
| by cycle 6 | 84.0 (63.9 to 95.5) |
| by cycle 9 | 88.0 (68.8 to 97.5) |
| by cycle 12 | 92.0 (74.0 to 99.0) |
| by cycle 18 | 92.0 (74.0 to 99.0) |
| by cycle 24 | 92.0 (74.0 to 99.0) |
| by cycle 36 | 92.0 (74.0 to 99.0) |
| by cycle 48 | 92.0 (74.0 to 99.0) |
| by cycle 66 | 92.0 (74.0 to 99.0) |
Complete Hematological Response (CHR) was defined as * WBC count \<10×109/L * platelet count \<450×109/L * basophils \<5% * no blasts and promyelocytes in peripheral blood * myelocytes+metamyelocytes \<5% in peripheral blood * no evidence of extramedullary disease, including spleen and liver * Assessment confirmation after at least 4 weeks for newly diagnosed Ph+ CML-CP
| months | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|
| Summary of Time to First Complete Hematological Response (CHR) Among Patients Who Achieved Confirmed CHR in Newly Diagnosed CML-CP Patients | 0.95 (0.72 to 2.76) |
Complete Hematological Response (CHR) was defined as * WBC count \<10×109/L * platelet count \<450×109/L * basophils \<5% * no blasts and promyelocytes in peripheral blood * myelocytes+metamyelocytes \<5% in peripheral blood * no evidence of extramedullary disease, including spleen and liver * Assessment confirmation after at least 4 weeks for newly diagnosed Ph+ CML-CP
| months | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|
| Kaplan-Meier Estimates of Time to First Complete Hematological Response (CHR) in Newly Diagnosed CML-CP Patients | 1.0 (1.0 to 2.8) |
Time to disease progression is the time from the date of first study drug intake to the date of event defined as the first progression to AP or BC (from CP) or to BC (from AP) or the date of CML-related death occurring on treatment, whichever was earlier.
| months | Resistant/Intolerant Ph+ CML in CP |
|---|---|
| Time to Disease Progression for Imatinib or Dasatinib Resistant or Intolerant CML-CP Patients - Kaplan-Meier Estimates | NA (NA to NA) |
Event Free Survival is defined as the time from the date of first study drug intake to the first occurrence of any of the following loss of CHR, loss of MCyR ( PCyR + CCyR), progression to AP/BC (from CP) or to BC (from AP), or death from any cause. (Including events only during treatment)
| months | Resistant/Intolerant Ph+ CML in CP |
|---|---|
| Event Free Survival in Imatinib/Dasatinib Resistant/Intolerant CML-CP Patients | NA (NA to NA) |
Event Free Survival is defined as the time from the date of first study drug intake to the first occurrence of any of the following loss of CHR, loss of MCyR ( PCyR + CCyR), progression to AP/BC (from CP) or to BC (from AP), or death from any cause. (Including events only during treatment)
| months | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|
| Event Free Survival in Newly Diagnosed CML-CP Patients | NA (NA to NA) |
Overall survival is defined as the time from the date of first study drug intake to the date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of their last assessment for patients on study and date of last contact for patients in follow-up.
| months | Resistant/Intolerant Ph+ CML in CP |
|---|---|
| Overall Survival (OS) in Imatinib/Dasatinib Resistant/Intolerant CML-CP - Kaplan-Meier Estimates | NA (NA to NA) |
Overall survival is defined as the time from the date of first study drug intake to the date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of their last assessment for patients on study and date of last contact for patients in follow-up.
| months | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|
| Overall Survival (OS) in Newly Diagnosed CML-CP Patients | NA (NA to NA) |
BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. BCR-ABL transcript levels were summarized by cohort and time point. MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR.
| Percentage of participants | Resistant/Intolerant Ph+ CML in CP | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|---|
| By Cycle 3 | 36.4 (20.4 to 54.9) | 12.0 (2.5 to 31.2) |
| By Cycle 6 | 45.5 (28.1 to 63.6) | 52.0 (31.3 to 72.2) |
| By Cycle 9 | 51.5 (33.5 to 69.2) | 56.0 (34.9 to 75.6) |
| By Cycle 12 | 57.6 (39.2 to 74.5) | 64.0 (42.5 to 82.0) |
| By Cycle 18 | 57.6 (39.2 to 74.5) | 68.0 (46.5 to 85.1) |
| By Cycle 24 | 57.6 (39.2 to 74.5) | 68.0 (46.5 to 85.1) |
| By Cycle 36 | 57.6 (39.2 to 74.5) | 76.0 (54.9 to 90.6) |
| By Cycle 48 | 60.6 (42.1 to 77.1) | 76.0 (54.9 to 90.6) |
| By Cycle 66 | 60.6 (42.1 to 77.1) | 76.0 (54.9 to 90.6) |
PK was analyzed only when all patients has completed 12 cycles on treatment or discontinued the study treatment early.
| ng/mL | Resistant/Intolerant Ph+ CML in CP |
|---|---|
| Pharmacokinetics (PK): Steady State Concentration of Nilotinib in Imatinib/Dasatinib Resistant/Intolerant CML-CP Patients | 1407.89 ± 41.67 |
PK was analyzed only when all patients has completed 12 cycles of treatment or discontinued the study treatment early.
| ng/mL | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|
| Pharmacokinetics: Steady State Concentration of Nilotinib in Newly Diagnosed CML-CP Patients | 1274.30 ± 46.21 |
To assess long term effect on growth, development and maturation of nilotinib treatment in pediatric patients with Ph+ CML in participants with both a baseline and post-baseline value.
| Percentage of participants | Resistant/Intolerant Ph+ CML in CP | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|---|
| Decrease from baseline of 1 SDS category (n=32,24) | 27.3 | 32.0 |
| Decrease from baseline of 2 SDS categories (n=32, 24) | 3.0 | 16.0 |
| Decrease from baseline of 3 SDS categories(n= 32, 24) | 6.1 | 4.0 |
Acceptability of the study drug was evaluated from a questionnaire completed by patients, with the help from parents or caregivers at visits. The Questionnaire to capture patient assessment of palatability (very good to very bad) and acceptability of taking the medication (very easy to very hard to administration).
| Percentage of participants | All Patients |
|---|---|
| Cycle (C) 1 Day (D) 1: Completed questionnaire - Patients | 75.9 |
| C1D1: Completed questionnaire - Parents/Caregivers | 22.4 |
| C1D1: Patients who swallowed capsule whole | 91.4 |
| C1D1: Patients had capsule mixed with apple sauce | 6.9 |
| C1D1: Patients who reported no taste/unable to answer question | 43.1 |
| C1D1: Patients who reported taste as good/very good | 12.1 |
| C1D1: Patients who reported taste as not good/not bad | 34.5 |
| C1D1: Reported capsule to be very easy/easy to administer | 79.3 |
| C1D28: Completed questionnaire - Patients | 55.2 |
| C1D28: Completed questionnaire - Parents/Caregivers | 22.4 |
| C12D28: Completed questionnaire - Patients | 55.2 |
| C12D28: Completed questionnaire - Parents/Caregivers | 22.4 |
Emerging signs of resistance to nilotinib
| Percentage of participants | Resistant/i Ntolerant Ph+ CML in CP | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|---|
| Patients with >=1 evaluable post-baseline mutational analysis | 39.4 | 32.0 |
| Patients with any emergent mutation on treatment | 0.0 | 0.0 |
| Patients with multiple emergent mutations on treatment | 0.0 | 0.0 |
The summary of bone age and Dual-energy X-ray absorptiometry (DEXA) by cohort. Alteration of bone biochemical markers of hand and wrist X-Ray evaluation was observed in bone age standard deviation scores (SDS) and for bone mineral density for DEXA before and after treatment with nilotinib.
| Percentage of participants | Resistant/Intolerant Ph+ CML in CP | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|---|
| X-ray (n= 6, 0) | -0.61 ± 1.703 | — |
| DEXA (n = 14, 10) | -0.35 ± 1.243 | -0.70 ± 1.043 |
On treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration of 64.5 months (treatment duration ranged from 0.7 to 63.5 months). Deaths post treatment survival follow up were collected after the on- treatment period, up to approx. 7 years.
| Participants | Resistant/Intolerant Ph+ CML in CP | Newly Diagnosed and Untreated Ph+ CML in First CP |
|---|---|---|
| On-treatment deaths | 0 | 0 |
| Total Deaths | 1 | 3 |
Collected over On treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration of 64.5 months (treatment duration ranged from 0.7 to 63.5 months). Deaths post treatment survival follow up were collected after the on- treatment period, up to approx. 7 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Resistant/Intolerant Ph+ CML in CP | 0/33 (0%) | 11/33 (33.3%) | 33/33 (100%) |
| Newly Diagnosed and Untreated Ph+ CML in First CP | 0/25 (0%) | 4/25 (16%) | 25/25 (100%) |
| All Patients | 0/58 (0%) | 15/58 (25.9%) | 58/58 (100%) |
| Event | Resistant/Intolerant Ph+ CML in CP | Newly Diagnosed and Untreated Ph+ CML in First CP | All Patients |
|---|---|---|---|
| PyrexiaGeneral disorders | 2/33 | 0/25 | 2/58 |
| Abdominal painGastrointestinal disorders | 0/33 | 1/25 | 1/58 |
| DiarrhoeaGastrointestinal disorders | 0/33 | 1/25 | 1/58 |
| HyperbilirubinaemiaHepatobiliary disorders | 0/33 | 1/25 | 1/58 |
| Gastroenteritis viralInfections and infestations | 1/33 | 1/25 | 2/58 |
| Viral infectionInfections and infestations | 1/33 | 1/25 | 2/58 |
| Electrocardiogram QT prolongedInvestigations | 0/33 | 1/25 | 1/58 |
| Weight decreasedInvestigations | 0/33 | 1/25 | 1/58 |
| Facial paralysisNervous system disorders | 0/33 | 1/25 | 1/58 |
| HeadacheNervous system disorders | 0/33 | 1/25 | 1/58 |
| Event | Resistant/Intolerant Ph+ CML in CP | Newly Diagnosed and Untreated Ph+ CML in First CP | All Patients |
|---|---|---|---|
| HeadacheNervous system disorders | 13/33 | 14/25 | 27/58 |
| Alanine aminotransferase increasedInvestigations | 10/33 | 11/25 | 21/58 |
| RashSkin and subcutaneous tissue disorders | 7/33 | 11/25 | 18/58 |
| NauseaGastrointestinal disorders | 8/33 | 10/25 | 18/58 |
| Blood bilirubin increasedInvestigations | 12/33 | 10/25 | 22/58 |
| PyrexiaGeneral disorders | 11/33 | 9/25 | 20/58 |
| Aspartate aminotransferase increasedInvestigations | 8/33 | 9/25 | 17/58 |
| VomitingGastrointestinal disorders | 7/33 | 8/25 | 15/58 |
| HyperbilirubinaemiaHepatobiliary disorders | 4/33 | 8/25 | 12/58 |
| Upper respiratory tract infectionInfections and infestations | 10/33 | 7/25 | 17/58 |
Full Analysis Set (FAS): All patients who received at least one dose of study medication.
| Age, Customized(Participants) | Resistant/Intolerant Ph+ CML in CP | Newly Diagnosed and Untreated Ph+ CML in First CP | Total |
|---|---|---|---|
| 1 to < 12 years | 12 | 6 | 18 |
| 12 to < 18 years | 21 | 19 | 40 |
| Sex: Female, Male(Participants) | Resistant/Intolerant Ph+ CML in CP | Newly Diagnosed and Untreated Ph+ CML in First CP | Total |
|---|---|---|---|
| Female | 12 | 12 | 24 |
| Male | 21 | 13 | 34 |
| Race/Ethnicity, Customized(Participants) | Resistant/Intolerant Ph+ CML in CP | Newly Diagnosed and Untreated Ph+ CML in First CP | Total |
|---|---|---|---|
| Caucasian | 12 | 18 | 30 |
| Black | 3 | 0 | 3 |
| Asian | 16 | 7 | 23 |
| Native American | 1 | 0 | 1 |
| Other | 1 | 0 | 1 |
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Aug 2013 to primary completion in Jun 2016, 33 months.
Results were first posted in May 2018, 1 year 11 months after primary completion.
Of 25 industry-sponsored phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 69. This study's 33 months is below that.
Counting every sponsor, half of 126 studies reached it within 73 months; a quarter within 43 and three quarters within 124.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nilotinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →